Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cytori Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: SnowShredder who wrote (8)	9/4/2005 7:54:23 PM
From: SnowShredder	Read Replies (1) \| Respond to of 251

IFATS 2005 fwiw... ifats.org ifats.org Best of Luck, SS >>> Meeting Information Location Omni Charlottesville Hotel 235 West Main Street Charlottesville , VA 22902 Phone: (434) 971-5500 Fax: (434) 979-4456 www.omnihotels.com Dates Saturday, September 10, 2005, 7:00 PM, through noon, Tuesday, September 13, 2005 The Meeting will kick off with a welcome reception on Saturday evening. Scientific sessions will be held on Sunday, Monday, and Tuesday morning and the Meeting will conclude by lunchtime on Tuesday.

To: SnowShredder who wrote (8)	6/15/2008 2:51:34 AM
From: SnowShredder	Read Replies (1) \| Respond to of 251

University of California Loses Rights to '231 Patent Licensed to Cytori; Ruling Unrelated to Celution(R) System Family of Products I'd imagine they knew this was worst case scenario from the get go, and prepared themselves just in case. Thus the "does not affect Cytori's commercialization of the Celution(R) System or the Company's product pipeline." We'll see how this plays out. ir.cytoritx.com Best of Luck, SS >>>>>>>> University of California Loses Rights to '231 Patent Licensed to Cytori; Ruling Unrelated to Celution(R) System Family of Products SAN DIEGO, Jun 12, 2008 (BUSINESS WIRE) -- The University of California inventors were removed from U.S. patent number 6,777,231, which was licensed to Cytori Therapeutics (NASDAQ: CYTX). The decision was made today by the United States District Court in the Central District of California. The '231 patent covers isolated adipose-derived stem cells and does not affect Cytori's commercialization of the Celution(R) System or the Company's product pipeline. However, Cytori believes that the court's decision is incorrect and that the University of California may elect to appeal the ruling. Cytori was recently granted a foundational patent on its Celution(R) System device technology for processing a mixture of adult stem and regenerative cells from adipose tissue. All patents within the Company's worldwide portfolio of issued and pending patent applications pertaining to the Celution(R) technology are owned by Cytori and not affected by this decision. Cytori Therapeutics Cytori Therapeutics' (NASDAQ:CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution(R) 800 System is being introduced in Europe into the reconstructive surgery market while the Celution(R) 900 System will be launched in Japan and Asia for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com Cautionary Statement Regarding Forward-Looking Statements This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori Therapeutics' Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made. SOURCE: Cytori Therapeutics Cytori Therapeutics Tom Baker, 858-875-5258 (Media & Investors) tbaker@cytoritx.com